Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.

2.

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.

BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

3.

The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.

Yang J, Sa M, Huang M, Yang J, Xiang Z, Liu B, Tang A.

Clin Biochem. 2013 Nov;46(16-17):1705-8. doi: 10.1016/j.clinbiochem.2013.08.019. Epub 2013 Sep 6.

PMID:
24012857
4.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
5.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
6.

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.

Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.

Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.

7.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

8.

The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.

Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075. Epub 2011 Feb 3.

PMID:
21288178
9.

HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Ortiz-Muñoz B, Aznar-Oroval E, García García A, Covisa Peris A, Perez Ballestero P, Sanchez Yepes M, Garcia Lozano T, Illueca Ballester C, García Garcia E.

Tumour Biol. 2014 Jul;35(7):7249-58. doi: 10.1007/s13277-014-1945-6. Epub 2014 Apr 27.

PMID:
24771264
10.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
11.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
12.

Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.

Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D; Australian Ovarian Cancer Study Group, Obermair A.

Gynecol Oncol. 2013 Jun;129(3):467-71. doi: 10.1016/j.ygyno.2013.03.001. Epub 2013 Mar 13.

PMID:
23500084
13.

The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.

Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.

Gynecol Oncol. 2013 Feb;128(2):239-44. doi: 10.1016/j.ygyno.2012.09.034. Epub 2012 Oct 10.

PMID:
23063998
14.

Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.

Dikmen ZG, Colak A, Dogan P, Tuncer S, Akbiyik F.

Eur J Gynaecol Oncol. 2015;36(4):457-62.

PMID:
26390703
15.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.

Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.

16.

The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.

Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, Imai Y, Nishikawa T, Oda K, Fujiwara K.

Oncol Res Treat. 2015;38(6):276-81. doi: 10.1159/000430858. Epub 2015 May 19.

PMID:
26045023
18.

Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R.

Tumour Biol. 2012 Dec;33(6):2117-23. doi: 10.1007/s13277-012-0471-7. Epub 2012 Aug 9.

PMID:
22875782
19.

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I.

Br J Cancer. 2011 Mar 1;104(5):863-70. doi: 10.1038/sj.bjc.6606092. Epub 2011 Feb 8.

20.

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP.

Clinics (Sao Paulo). 2012;67(5):437-41.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk